Compassher2 pcr
WebJan 10, 2024 · This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no … WebMay 10, 2024 · The CompassHER2-pCR trial (NCT04266249) is ongoing and will determine recurrence-free survival among patients with HER2+ breast cancer who receive an abbreviated neoadjuvant regimen and experience ...
Compassher2 pcr
Did you know?
WebEA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response. Status: Recruiting. I'm interested. Facebook Twitter. Email. Download PDF Eligibility Criteria; Conditions & Interventions; More Information; Sex: Male or Female. Age: 18 Years and over. WebJul 2, 2024 · Ongoing clinical trials are testing this strategy (CompassHER2-pCR: NCT04266249). pCR also provides an opportunity to assess de-escalation of locoregional therapies. Currently, for patients with residual disease in the lymph nodes (ypN+), radiation therapy entails coverage of the undissected axilla, and may include supra/infraclavicular ...
WebCompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (Study ID: EA1181) Phase: II Physician … WebMay 18, 2024 · I’m going to let everybody know about a very important trial called CompassHER2-pCR, which offers the potential to avoid both anthracycline and carboplatin. I want to nickname this the “let’s get rid of carboplatin” trial. But patients get weekly paclitaxel with trastuzumab and pertuzumab preoperatively, and those patients who have …
WebARM A: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Patients may substitute trastuzumab-hyaluronidase SC over 2-5 minutes on day 1 in place of trastuzumab or pertuzumab-trastuzumab-hyaluronidase SC over 5 minutes on day 1 in place of trastuzumab and pertuzumab. Treatment repeats every 21 days for up to 13 ... WebSite for EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Brief description of study The purpose of …
WebMay 10, 2024 · The CompassHER2-pCR trial (NCT04266249) is ongoing and will determine recurrence-free survival among patients with HER2+ breast cancer who …
WebARM A: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease … bolt together boat docksWebInformation about IUSCCC Clinical Trial CTO-EA1181: EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) bolt together gun cabinetWebFeb 11, 2024 · SWOG clinical trial number. CTSU/EA1181. (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response. Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) … bolt together handrailWebFeb 11, 2024 · End Date: February 28, 2024. Summary: This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after … gmc service manuals onlineWebThe CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease … bolt together hopper bottoms for grain binsWebSep 17, 2024 · The CompassHER2-pCR trial is evaluating the impact of de-escalating chemotherapy in patients achieving pCR and escalating treatment in those with residual disease. Similarly, a second trial – the DECRESCENDO trial – will de-escalate adjuvant chemotherapy in patients with breast cancer, hormone receptor-negative and node … bolt together ar lowerWebMay 18, 2024 · In fact, there are multiple clinical trials ongoing for early stage disease. One example is a trial that’s really looking at de-escalation of therapy in this setting. For example, CompassHER2-pCR is a large cooperative group trial, which is looking at preoperative THP [docetaxel, trastuzumab, pertuzumab]—for 12 weeks, trastuzumab, and ... gmc services limited